Frontiers journals are at the top of citation and impact metrics
Women’s Cancer is a specialty section of Oncology dedicated to advancing scientific and clinical knowledge of breast and gynecologic cancers. This section seeks to publish articles addressing novel findings, controversies, and innovative hypotheses in the areas of prevention, diagnosis, and treatment of breast and gynecologic malignancies. The primary focus however is on the development of a personalized and tailored approach to the prevention and treatment of breast and gynecologic malignancies. These articles will include epidemiologic, basic science, translational and clinical studies. The interactive online forum will allow rapid review and dissemination of these important papers in an open access format. Specific topics to be covered include:
Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
PMCID: coming soon for all published articles
Women's Cancer welcomes submissions of the following article types: Case Report, Clinical Trial, Correction, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology Report.
All manuscripts must be submitted directly to the section Women's Cancer, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Women's Cancer will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Oncology.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com